| Name | Title | Contact Details |
|---|
Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.
MAKE AN APPOINTMENT Adult: 210.261.1250 Children: 210.261.3350 The Center for Health Care Services (CHCS) is proud to present our Annual Report for Fiscal Year 2018. By making Our People, Our Community, Our Priority; CHCS is changing lives, restoring...
AzoRx, Inc. is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.